FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010112829> ?p ?o ?g. }

• W2010112829 endingPage "37" @default.
• W2010112829 startingPage "27" @default.
• W2010112829 abstract "AIMS To evaluate the influence of cytochrome P450 (CYP) 3A4 inhibitors on the clinical pharmacokinetics of maraviroc, a novel CCR5 antagonist. METHODS Four open-label, randomized, placebo-controlled studies were conducted in healthy subjects to assess the effect of separate and distinct combinations of CYP3A4 inhibitors on the steady-state pharmacokinetics of maraviroc. Study 1 was a two-way crossover study investigating the influence of saquinavir (SQV; 1200 mg t.i.d.) and ketoconazole (400 mg q.d.) on the pharmacokinetics of maraviroc (100 mg b.i.d.). All subjects received maraviroc for 7 days in both study periods. Cohort 1 subjects also received SQV or placebo and cohort 2 subjects also received ketoconazole or placebo. Study 2 was a parallel-group study including four treatment groups investigating the effects of ritonavir-boosted lopinavir (LPV/r; 400 mg/100 mg b.i.d.), ritonavir-boosted saquinavir (SQV/r; 1000 mg/100 mg b.i.d.), and low-dose ritonavir (RTV; 100 mg b.i.d.) on the steady-state pharmacokinetics of maraviroc (100 mg b.i.d.), and exploring whether maraviroc dose adjustment can compensate for interaction effects. Treatment lasted 28 days and comprised three distinct phases: (i) maraviroc alone on days 1–7; (ii) maraviroc + interactant on days 8–21; and (iii) maraviroc (adjusted dose) + interactant on days 22–28. Study 3 was a two-way crossover study investigating the effects of atazanavir (ATZ; 400 mg q.d.) and ritonavir-boosted atazanavir (ATZ/r; 300 mg/100 mg b.i.d.) on the pharmacokinetics of maraviroc (300 mg b.i.d.). All subjects received maraviroc on days 1–14 of both study periods. Subjects also received ATZ on days 1–7 and ATZ/r on days 8–14 of one treatment period, and placebo on days 1–14 of the other treatment period. Study 4 was a two-way crossover study investigating the effects of ritonavir-boosted tipranavir (TPV/r; 500 mg/200 mg b.i.d.) on the pharmacokinetics of maraviroc (150 mg b.i.d.). Subjects received maraviroc plus TPV/r or placebo on days 1–8. RESULTS All of the drugs/drug combinations tested (except for TPV/r) increased maraviroc exposure, albeit to different degrees of magnitude. SQV/r caused the largest increase in maraviroc exposure (8.3-fold increase in AUCτ), whereas RTV caused the smallest increase in maraviroc exposure (2.6-fold increase in AUCτ). Downward adjustment of the maraviroc dose in study 2 during co-administration of HIV protease inhibitors was able to compensate for the interactions. TPV/r had no clinically relevant effect on maraviroc exposure at steady state. There were no treatment-related serious adverse events or discontinuations due to adverse events in any of the studies, and most adverse events were mild or moderate in severity and resolved without intervention. CONCLUSIONS Potent CYP3A4 inhibitors, including ketoconazole and protease inhibitors (except TPV/r), increase maraviroc exposure. Downward adjustment of the maraviroc dose during co-administration with protease inhibitors can compensate for the interaction. TPV/r does not affect the steady-state pharmacokinetics of maraviroc, and hence no dose adjustment would be warranted." @default.
• W2010112829 created "2016-06-24" @default.
• W2010112829 creator A5010622611 @default.
• W2010112829 creator A5019219577 @default.
• W2010112829 creator A5056696602 @default.
• W2010112829 creator A5061029367 @default.
• W2010112829 creator A5079055631 @default.
• W2010112829 date "2008-04-01" @default.
• W2010112829 modified "2023-10-03" @default.
• W2010112829 title "Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers" @default.
• W2010112829 cites W1651794786 @default.
• W2010112829 cites W1848709375 @default.
• W2010112829 cites W1965508366 @default.
• W2010112829 cites W1981719094 @default.
• W2010112829 cites W2002127959 @default.
• W2010112829 cites W2011753619 @default.
• W2010112829 cites W2039244520 @default.
• W2010112829 cites W2067274937 @default.
• W2010112829 cites W2068946470 @default.
• W2010112829 cites W2071998110 @default.
• W2010112829 cites W2075870842 @default.
• W2010112829 cites W2076915947 @default.
• W2010112829 cites W2078387155 @default.
• W2010112829 cites W2078604812 @default.
• W2010112829 cites W2090632754 @default.
• W2010112829 cites W2092806574 @default.
• W2010112829 cites W2109313097 @default.
• W2010112829 cites W2117378263 @default.
• W2010112829 cites W2154989704 @default.
• W2010112829 cites W2163690468 @default.
• W2010112829 cites W2339827976 @default.
• W2010112829 cites W2916542119 @default.
• W2010112829 cites W4235219016 @default.
• W2010112829 doi "https://doi.org/10.1111/j.1365-2125.2008.03133.x" @default.
• W2010112829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2311406" @default.
• W2010112829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18333863" @default.
• W2010112829 hasPublicationYear "2008" @default.
• W2010112829 type Work @default.
• W2010112829 sameAs 2010112829 @default.
• W2010112829 citedByCount "81" @default.
• W2010112829 countsByYear W20101128292012 @default.
• W2010112829 countsByYear W20101128292013 @default.
• W2010112829 countsByYear W20101128292014 @default.
• W2010112829 countsByYear W20101128292015 @default.
• W2010112829 countsByYear W20101128292016 @default.
• W2010112829 countsByYear W20101128292017 @default.
• W2010112829 countsByYear W20101128292018 @default.
• W2010112829 countsByYear W20101128292019 @default.
• W2010112829 countsByYear W20101128292020 @default.
• W2010112829 countsByYear W20101128292021 @default.
• W2010112829 countsByYear W20101128292022 @default.
• W2010112829 countsByYear W20101128292023 @default.
• W2010112829 crossrefType "journal-article" @default.
• W2010112829 hasAuthorship W2010112829A5010622611 @default.
• W2010112829 hasAuthorship W2010112829A5019219577 @default.
• W2010112829 hasAuthorship W2010112829A5056696602 @default.
• W2010112829 hasAuthorship W2010112829A5061029367 @default.
• W2010112829 hasAuthorship W2010112829A5079055631 @default.
• W2010112829 hasBestOaLocation W20101128291 @default.
• W2010112829 hasConcept C109650736 @default.
• W2010112829 hasConcept C112705442 @default.
• W2010112829 hasConcept C126322002 @default.
• W2010112829 hasConcept C142462285 @default.
• W2010112829 hasConcept C142724271 @default.
• W2010112829 hasConcept C159047783 @default.
• W2010112829 hasConcept C16005928 @default.
• W2010112829 hasConcept C204787440 @default.
• W2010112829 hasConcept C22979827 @default.
• W2010112829 hasConcept C27081682 @default.
• W2010112829 hasConcept C2776937687 @default.
• W2010112829 hasConcept C2778414717 @default.
• W2010112829 hasConcept C2778899366 @default.
• W2010112829 hasConcept C2779298103 @default.
• W2010112829 hasConcept C2779548794 @default.
• W2010112829 hasConcept C2781064554 @default.
• W2010112829 hasConcept C2993143319 @default.
• W2010112829 hasConcept C3013748606 @default.
• W2010112829 hasConcept C526171541 @default.
• W2010112829 hasConcept C62231903 @default.
• W2010112829 hasConcept C71924100 @default.
• W2010112829 hasConcept C87813604 @default.
• W2010112829 hasConcept C97320921 @default.
• W2010112829 hasConcept C98274493 @default.
• W2010112829 hasConceptScore W2010112829C109650736 @default.
• W2010112829 hasConceptScore W2010112829C112705442 @default.
• W2010112829 hasConceptScore W2010112829C126322002 @default.
• W2010112829 hasConceptScore W2010112829C142462285 @default.
• W2010112829 hasConceptScore W2010112829C142724271 @default.
• W2010112829 hasConceptScore W2010112829C159047783 @default.
• W2010112829 hasConceptScore W2010112829C16005928 @default.
• W2010112829 hasConceptScore W2010112829C204787440 @default.
• W2010112829 hasConceptScore W2010112829C22979827 @default.
• W2010112829 hasConceptScore W2010112829C27081682 @default.
• W2010112829 hasConceptScore W2010112829C2776937687 @default.
• W2010112829 hasConceptScore W2010112829C2778414717 @default.
• W2010112829 hasConceptScore W2010112829C2778899366 @default.
• W2010112829 hasConceptScore W2010112829C2779298103 @default.
• W2010112829 hasConceptScore W2010112829C2779548794 @default.

• next